These are the stocks posting the largest moves before the bell.Market Insiderread more
"That's my view. They'll cut preemptively in June. That is to say Wednesday," says the Grant's Interest Rate Observer newsletter editor.Economyread more
The Fed is not likely to make a move on interest rates when it meets this week, but it should clear the way for a rate cut later in the summer.Market Insiderread more
Ross played down the prospect of an agreement being reached at the G-20 meeting in Osaka on June 28-29.Paris Airshowread more
Boeing is scrambling to restore confidence in the 737 Max from regulators, customers and the flying public.Paris Airshowread more
The chipmaker crush could persist and investors should be selective, but Nvidia looks like a clear buy, one market watcher says.Trading Nationread more
Heavy rains caused unprecedented delays in planting this year and contributed to record floods across the central United States.Agricultureread more
Here are the biggest calls on Wall Street on MondayInvestingread more
In a rare downgrade for the stock, Imperial Capital lowered its rating for Disney to in-line from outperform and maintained its target price of $147.Investingread more
GM CEO Mary Barra promised the automaker would launch 20 models of electric cars by 2023, beginning early this year. That plan may stall. A slowdown in China, a ratcheting up...Evolveread more
Senior economists from both political parties say a rate cut may not work that smoothly even if the Fed says yes. And that poses risks to America's decade-long recovery as the...Politicsread more
British artificial intelligence start-up BenevolentAI has bagged $115 million from investors, lifting its pre-money valuation to $2 billion.
The London-based firm, which is focused on the pharmaceutical industry, said the latest round of funding will help it scale drug development and its AI platform.
The company currently has more than 20 drug programs. It said it will use the raised capital to expand into other areas of the market like advanced materials, agriculture and energy storage.
Its AI technology is used to decipher the molecular process of disease and match drug treatments to the most applicable patients.
BenevolentAI created a bioscience machine "brain" that uses algorithms and data to locate the cause of diseases and generate insights into them that humans otherwise couldn't. Its platform is being used to develop treatments for incurable diseases like motor neurone disease, Parkinson's disease, glioblastoma and sarcopenia.
Some worry that the U.K.'s decision to leave the European Union could hamper innovation and scientific research. The EU's single market lets firms move goods, capital, services and labor freely and the soon-to-be 27-member bloc offers funding schemes for science and research programs.
But Ken Mulvany, founder and chairman of BenevolentAI, said that Britain remained an attractive hub for science.
"There's a tremendous heritage of scientific innovation here in the U.K.," he told CNBC's "Street Signs Europe." "It certainly has been batting well above its weight in that respect."
The British government launched an initiative last year to boost skills and education and grow the country's AI industry. Mulvany said the government's strategy on AI was positive for the sector.
"The U.K. is one of the leading sectors for AI innovation," Mulvany said. "You see it in Toronto, you see it in Stanford and we're seeing it in the knowledge quarter here in London."